Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 8/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | ME3 | Q16798 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14321881 | 0.91 | DRD2 (0.42) | NPY5RUSP30MTNR1AMTNR1BDRD2 | |
| SCHEMBL14328872 | 0.89 | NPY5R (0.41) | NPY5REPHX2USP30MTNR1AMTNR1B | |
| SCHEMBL14322325 | 0.85 | PKM (0.45) | NPY5RMTNR1AMTNR1BME3SMN1; SMN2 | |
| SCHEMBL14328869 | 0.85 | USP30 (0.46) | USP30DRD2DRD3 | |
| SCHEMBL22290809 | 0.82 | LIPG (0.40) | NOTUMFFAR4SMN1; SMN2 | |
| SCHEMBL13420961 | 0.81 | NOTUM (0.60) | NOTUM | |
| SCHEMBL27312501 | 0.80 | LPL (0.41) | SMN1; SMN2MEN1MAPTHTTKMT2A | |
| SCHEMBL3374553 | 0.80 | NOTUM (0.46) | NOTUMMTNR1AMTNR1BSMN1; SMN2MEN1 | |
| SCHEMBL14905664 | 0.80 | EPHX2 (0.43) | NOTUMEPHX2SMN1; SMN2MEN1MAPT | |
| SCHEMBL901893 | 0.80 | USP2 (0.42) | SMN1; SMN2MEN1MAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723741-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2016-04-27 | — | — | EP | disclosed |
| US-8962619-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. | 2014-03-13 | — | — | US | disclosed |
| US-8609688-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ArQuele, Inc. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329791-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | NPY5R 1824/4885NOTUM 3885/4885EPHX2 3742/4885 |
| US-20140073635-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | NPY5R 1824/4885NOTUM 3885/4885EPHX2 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.